Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer

Diseases of the Esophagus

Volumn 21, Issue 8, 2008, Pages 697-703

  Cho, S H ^a   Shim, H J ^a   Lee, S R ^a   Ahn, J S ^a   Yang, D H ^a   Kim, Y K ^a   Nam, T K ^b   Lee, J J ^a   Kim, H J ^a   Chung, Ik Joo ^a  

^a Chonnam National University Research Institute of Medical Sciences   (South Korea)

^b Chonnam National University Medical School   (South Korea)

Author keywords

Chemoradiotherapy; Cisplatin; Esophageal cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER STAGING; CLINICAL ARTICLE; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ODYNOPHAGIA; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; RADIATION DOSE; STOMATITIS; THROMBOCYTOPENIA; TRACHEOESOPHAGEAL FISTULA; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COHORT STUDIES; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ESOPHAGEAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PILOT PROJECTS; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 55249113352     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2008.00837.x     Document Type: Article

References (40)

1. Muller J M, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical therapy of oesophageal carcinoma. Br J Surg 1990; 77: 845-57.
2. Kelsen D P, Ginsberg R, Pajak T F et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-84.
3. Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-17.
4. Bedenne L, Michel P, Bouche O et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25: 1160-8.
5. Bleiberg H, Conroy T, Paillot B et al. Randomised phase II study of cisplatin and 5-fluorouracil versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997; 33: 1216-20.
6. Ohtsu A, Boku N, Muro K et al. Definitive chemoradiotherapy for T4 and/ or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999; 17: 2915-21.
7. Forastiere A A, Orringer M B, Perez-Tamayo C, Urba SG, Zahurak M. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: Final report. J Clin Oncol 1993; 11: 1118-23.
8. Shirasaka T, Shimamato Y, Ohshimo H et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two chemical modulators. Anticancer Drugs 1996; 7: 548-57.
9. Takechi T, Nakano K, Uchida J et al. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemothe Pharmacol 1997; 39: 205-11.
10. Hirata K, Horikoshi N, Aibe K et al. Phamacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999; 5: 2000-5.
11. Shirasaka T, Shimamato Y, Ohshimo H et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548-57.
12. Koizumi W, Kurihara M, Nakano S et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000; 58: 191-7.
13. Koizumi W, Tanabe S, Saigenji K et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003; 89: 2207-12.
14. Sato Y, Kondo H, Honda K et al. A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen. Int J Clin Oncol 2005; 10: 40-4.
15. Nakata B, Mitachi Y, Tsuji A et al. Combination phase I trial of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902). Clin Cancer Res 2004; 10: 1664-9.
16. Kimura Y, Kikkawa N, Iijima S et al. A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: Efficacy and feasibility in clinical practice. Gastric Cancer 2003; 6 (Suppl 1): 34-9.
17. Halvorsen R A Jr, Magruder-Habib K, Foster W L Jr et al. Esophageal cancer staging by computed tomography long-term follow-up study. Radiology 1986; 161: 147-51.
18. Miller A B, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 207-14.
19. Johnston L F, DeMeester T R. Twenty-four-hour pH monitoring of the distal esophagus. Am J Gastroenterol 1974; 62: 325-32.
20. Bedenne L, Michel P, Bouche O et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25: 1160-8.
21. Homs M Y, vd Gaast A, Siersema P D et al. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev. 2006; 18: CD004063.
22. Benulic T, Jucar B. Treatment of advanced esophageal cancer by means of irradiation, cisplatin and 5-fluorouracil. Neoplasma 1995; 42: 141-5.
23. Herskovic A, Marts K, al-Sarraf M et al. Combined chemotherapy and radiotherapy complared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1991; 326: 1593-8.
24. al Sarraf M, Martz K, Herskovic A et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study. J Clin Oncol 1997; 15: 277-84.
25. Shirasaka T, Shimamoto Y, Ohshima H, Saito J, Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993; 32: 167-71.
26. Ha J W, Chung H C, Kim D L et al. A phase II trial of combined sequential FP (5-FU+cisplatin) chemotheraphy and radiotherapy in locally advanced unresectable esophageal cancer. J Korean Cancer Assoc 1991; 23: 307-14.
27. Ikenaka K, Shirasaka T, Kitano S, Fuiji S. Effects of uracil on metabolism of 5-fluorouracil in vitro. Gann 1979; 70: 53-9.
28. Etienne M C, Cheradame S, Fischel J L et al. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropymidine dehydrogenase activity. J Clin Oncol 1995; 13: 1663-70.
29. Heggie G D, Sommadossi J P, Cross D S, Huster W J, Diasio R B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47: 2203-6.
30. Zhang R, Lu Z, Liu T, Soong S J, Diasio R B. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes. Cancer Res 1993; 53: 2816-22.
31. Beck A, Etienne M C, Cheradame S et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 1994; 30: 1517-22.
32. Fukushima M, Shimamoto Y, Kato T etal. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. of 5-fluorouracil. Anticancer Drugs 1998; 9: 817-23.
33. Shirasaka T, Shimamato Y, Ohshimo H et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548-57.
34. Conroy T, Etienne P L, Adenis A et al. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: Response, toxicity, quality of life, and survival. Ann Oncol 2002; 13: 721-9.
35. Thomas A L, O'Byrne K, Steward S P. Chemotherapy for upper gastrointestinal tumours. Postgrad Med J 2000; 76: 321-7.
36. Gignoux M, Bosset J, Apoil B et al. Adjuvant radiochemotherapy in operable cancers of the thoracic esophagus. Preliminary results of a multicenter study. A study of 119 cases. Ann Chir 1989; 43: 269-74.
37. Poplin E, Fleming T, Leichman L et al. Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037). J Clin Oncol 1987; 5: 622-8.
38. Iwase H, Shimada M, Nakamura M et al. Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: Longterm results of a phase II study of UFT/CDDP with radiotherapy. Int J Clin Oncol 2003; 8: 305-11.
39. Levard H, Pouliquen X, Hay JM et al. 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research. Eur J Surg 1998; 164: 849-57.
40. Burmeister B H, Smithers M B, Fiztgerald L et al. A randomized phase III trial of preoperative chemoradiation followed by surgery versus surgery alone for localized resectable cancer of the esophagus. Proc Am Soc Clin Oncol 2002; 21: 518.